Journal
BIOLOGICAL PSYCHIATRY
Volume 68, Issue 11, Pages 1073-1076Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2010.07.015
Keywords
Children; cognitive-behavioral therapy; D-cycloserine; obsessive-compulsive disorder; outcome; treatment
Categories
Funding
- National Institutes of Health [MH076775, L40 MH081950-02]
- National Alliance for Research on Schizophrenia and Affective Disorders
- National Institute of Mental Health (NIMH)
- National Institute of Child Health and Human Development
- All Children's Hospital Research Foundation
- Centers for Disease Control
- Obsessive-Compulsive Foundation
- Tourette Syndrome Association
- Janssen Pharmaceuticals
- Foundation for Research on Prader-Willi Syndrome
- Forest Laboratories
- Endo
- International OCD Foundation
- Joseph Drown Foundation
- Friends of the Semel Institute
- Oxford University Press
- AstraZeneca
- Lilly
- McNeil Pediatrics
- Shire
- Forest Laboratories, Inc.
- Sanofi Aventis
- Janssen
- Pfizer
- Bristol-Myers Squibb
- Michael A. Jenike Endowed Fund
- Food and Drug Administration
- Elsevier Publications
- Guilford Publications
- New Harbinger Publications
- Boehringer Ingelheim
- National Institute of Neurological Disorders and Stroke
- Eli Lilly and Co.
- GlaxoSmithKline
- Otsuka
- Wallace Foundation
- Pediatric Obsessive Compulsive and Related Disorders
- McIngvale Family Foundation
Ask authors/readers for more resources
Background: Research on the neural circuitry underlying fear extinction has led to the examination of D-cycloserine (DCS), a partial agonist at the N-methyl-D-aspartate receptor in the amygdala, as a method to enhance exposure therapy outcome. Preliminary results have supported the use of DCS to augment exposure therapy in adult anxiety disorders; however, no data have been reported in any childhood anxiety disorder. Thus, we sought to preliminarily examine whether weight-adjusted DCS doses (25 or 50 mg) enhanced the overall efficacy of cognitive-behavioral therapy (CBT) for pediatric obsessive-compulsive disorder (OCD). Method: Participants were 30 youth (aged 8-17) with a primary diagnosis of OCD. The study design was a randomized, double-blinded, placebo-controlled augmentation trial examining CBT + DCS versus CBT + Placebo (15 youth per group). All patients received seven exposure and response prevention sessions paired with DCS or placebo taken 1 hour before sessions. Results: Although not significantly different, compared with the CBT + Placebo group, youth in the CBT + DCS arm showed small-tomoderate treatment effects (d = .31-.47 on primary outcomes). No adverse events were recorded. Conclusions: These results complement findings in adult OCD and non-OCD anxiety disorders and provide initial support for a more extensive study of DCS augmentation of CBT among youth with OCD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available